The foundational rule non-US device companies must understand
Under 21 CFR 812.18(a), a company outside the United States cannot itself sponsor an FDA Investigational Device Exemption (IDE) study. A US person or entity must hold the sponsor designation and bear the full weight of that role. This is not a technicality that can be papered over with an assignment clause or a CRO engagement letter. The obligation is structural, and it shapes every downstream compliance requirement in a US clinical study, including two that trip up international sponsors more than almost any other: investigator agreements and financial disclosure.
If your device company is headquartered in Germany, Japan, Israel, or anywhere outside the United States, you need a contracted US sponsor of record before your IDE study begins. That sponsor executes agreements and collects disclosures on your behalf, but the regulatory obligations never transfer away from the sponsor role itself. Understanding exactly what those obligations require, and why they are distinct from each other, is the first step toward building a compliant study program.
What a sponsor investigator agreement must cover and why financial disclosure is separate
A sponsor's investigator agreement under 21 CFR 812.43 is a written commitment from each clinical investigator to conduct the study according to the signed investigational plan, the IDE application, and all applicable FDA regulations. It documents the investigator's responsibilities for device accountability, recordkeeping, subject protection, and adverse event reporting. The agreement establishes the legal relationship between the sponsor and the site before a single subject is enrolled.
Financial disclosure is collected separately because it serves a different regulatory purpose. Financial relationships between sponsors and clinical investigators can create bias that affects data integrity, and FDA must be able to assess those relationships when it reviews a marketing submission. As 21 CFR 812.43(c) states: 'each investigator shall sign a statement, provided by the sponsor, that contains...the investigator's qualifications and a commitment to conduct the investigation in accordance with the agreement.' That commitment, embedded in the signed agreement, is the anchor point for site accountability. Financial disclosure documentation, governed separately by 21 CFR Part 54, captures the financial interests of clinical investigators and their immediate families to allow FDA reviewers to assess whether disclosed interests could have influenced study outcomes. The two collections overlap in timing but address entirely different regulatory questions.
How a contracted US sponsor of record executes these obligations
When a non-US device company engages a contracted US sponsor of record, that sponsor prepares and executes investigator agreements under 21 CFR 812.43(c) on the sponsor's behalf. The contracted entity administers the paperwork, manages the site file, and coordinates collection of financial disclosure certifications and disclosures required under 21 CFR Part 54. A CRO may handle the operational workflow, but the CRO does not hold the sponsor designation. The contracted US sponsor of record does.
This distinction matters enormously when FDA sends a warning letter or requests inspection records. The agency looks to the sponsor of record for compliance, not to the CRO, not to the foreign parent company, and not to the contract manufacturer. The underlying 812.43(c) obligation stays with the sponsor of record, always. No contract language transfers it elsewhere. If your CRO has told you it will act as sponsor, review that claim carefully against 21 CFR 812.18(a) and the guidance at adbccro.com/cro-wont-act-as-us-sponsor-now-what. If you are still uncertain about who carries liability in your IDE study structure, the analysis at adbccro.com/who-is-liable-in-a-us-ide-study walks through the key scenarios in plain language.
Practical steps for international device companies preparing an IDE study
- Identify your contracted US sponsor of record before submitting or amending any IDE application.
- Confirm that investigator agreement templates reference 21 CFR 812.43(c) and are reviewed against your specific study design, including whether your device qualifies as nonsignificant risk.
- Build financial disclosure collection into site initiation workflows, not as an afterthought before database lock.
- Review your CRO scope of work to confirm it does not blur the line between operational support and regulatory sponsorship.
- Retain all signed agreements and financial disclosure forms in the study master file in a format accessible to FDA upon request.
ADB Consulting and CRO Inc. serves as the contracted US sponsor of record for non-US medical device companies conducting FDA-regulated clinical studies in the United States.
For a full picture of how clinical trial services are structured under a contracted US sponsor model, visit adbccro.com/clinical-trial-services.
Reviewed November 21, 2026 by ADB's regulatory team.
If your company is preparing an IDE study or reviewing an existing sponsor structure, ADB's regulatory team is ready to help you assess the gaps and prepare a compliant path forward. Book a free discovery call at adbccro.com and speak directly with the team that manages US sponsor of record engagements every day.
Frequently asked questions
Can a non-US company be listed as the sponsor on an FDA IDE application?
No. Under 21 CFR 812.18(a), only a US person or entity may sponsor an FDA IDE study. A non-US company must designate a contracted US sponsor of record who holds the regulatory obligations and executes all sponsor responsibilities, including investigator agreements and financial disclosure collection, for the duration of the study.
Does a CRO executing investigator agreements on behalf of a sponsor become the sponsor of record?
No. A CRO that prepares, distributes, and collects investigator agreements is performing an operational service. The 21 CFR 812.43(c) obligation resides with the sponsor of record, not with the service provider administering the paperwork. FDA holds the named sponsor accountable in any inspection or enforcement action, regardless of which entity handled document logistics.
When must financial disclosure forms under 21 CFR Part 54 be collected?
Financial disclosure certifications and disclosure forms should be collected before study initiation at each site and updated whenever a clinical investigator's financial interests change materially during the study. These records must be retained and submitted as part of the marketing application so FDA reviewers can assess whether any disclosed financial interests could affect the reliability of the study data.
Related reading: our clinical trial data management support covers this in more depth.
Ready to Navigate the FDA Process with Confidence?
Book a free 30-minute discovery call with ADB's regulatory team to discuss your specific device and situation.
Book a Free Pathway Call